ADVFN
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,098.18
      1.21%
      US Tech 100
      21,605.40
      1.60%
      Dow Jones
      43,119.87
      1.26%
      Brent Oil
      66.595
      -4.66%
      Bitcoin
      105,531.62
      0.05%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Molecular Partners AG (MOLN) Quote

      Molecular Partners AG

      Molecular Partners AG (MOLN)

      NASDAQ
      3.52
      -0.06
      ( -1.68% )
      Updated: 13:45:28
      15 min delayed - Upgrade to Realtime

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      3.52
      Bid
      3.58
      Ask
      3.77
      Volume
      133
      3.52 Day's Range 3.52
      0.00 52 Week Range 0.00
      Market Cap
      142.078M
      Previous Close
      3.58
      Open
      3.52
      Last Trade
      1
      @
      3.5701
      Last Trade Time
      14:05:47
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      -
      Shares Outstanding
      40,363,095
      Dividend Yield
      -
      PE Ratio
      -18.82
      Earnings Per Share (EPS)
      -1.34
      Revenue
      4.97M
      Net Profit
      -54.04M

      About Molecular Partners AG

      Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseas... Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.molecularpartners.com
      Headquarters
      Schlieren, Che
      Founded
      -
      Molecular Partners AG is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MOLN. The last closing price for Molecular Partners was $3.58. Over the last year, Molecular Partners shares have traded in a share price range of $ 0.00 to $ 0.00.

      Molecular Partners currently has 40,363,095 shares outstanding. The market capitalization of Molecular Partners is $144.50 million. Molecular Partners has a price to earnings ratio (PE ratio) of -18.82.

      Ask ADVFN Intelligence (AI)

      MOLN Latest News

      More News

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      June 12 2025
      MOLN (-1.68%)

      Form EFFECT - Notice of Effectiveness
      Edgar (US Regulatory)
      April 25 2025
      MOLN (-1.68%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000DR
      40000000DR
      120000000DR
      260000000DR
      520000000DR
      1560000000DR
      2600000000DR

      MOLN - Frequently Asked Questions (FAQ)

      What is the current Molecular Partners share price?
      The current share price of Molecular Partners is $ 3.52
      How many Molecular Partners shares are in issue?
      Molecular Partners has 40,363,095 shares in issue
      What is the market cap of Molecular Partners?
      The market capitalisation of Molecular Partners is USD 144.5M
      What is the 1 year trading range for Molecular Partners share price?
      Molecular Partners has traded in the range of $ 0.00 to $ 0.00 during the past year
      What is the PE ratio of Molecular Partners?
      The price to earnings ratio of Molecular Partners is -18.82
      What is the cash to sales ratio of Molecular Partners?
      The cash to sales ratio of Molecular Partners is 204.71
      What is the reporting currency for Molecular Partners?
      Molecular Partners reports financial results in CHF
      What is the latest annual turnover for Molecular Partners?
      The latest annual turnover of Molecular Partners is CHF 4.97M
      What is the latest annual profit for Molecular Partners?
      The latest annual profit of Molecular Partners is CHF -54.04M
      What is the registered address of Molecular Partners?
      The registered address for Molecular Partners is WAGISTRASSE 14, SCHLIEREN, 8952
      What is the Molecular Partners website address?
      The website address for Molecular Partners is www.molecularpartners.com
      Which industry sector does Molecular Partners operate in?
      Molecular Partners operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      NKTRNektar Therapeutics
      $ 24.82
      (160.17%)
      		28.6M
      ONMDOneMedNet Corporation
      $ 0.731999
      (115.29%)
      		461.26M
      YAASYouxin Technology Ltd
      $ 5.39
      (88.79%)
      		17.47M
      EYENEyenovia Inc
      $ 9.315
      (69.98%)
      		39.8M
      SOGPSound Group Inc
      $ 4.1536
      (57.93%)
      		1.51M
      UPXIUpexi Inc
      $ 3.925
      (-60.75%)
      		4.89M
      GIBOGIBO Holdings Ltd
      $ 0.3991
      (-29.49%)
      		23.87M
      RBNERobin Energy Ltd
      $ 4.89
      (-27.01%)
      		2.43M
      XTKGX3 Holdings Company Ltd
      $ 1.61
      (-26.82%)
      		74.86k
      MAASMaase Inc
      $ 7.33
      (-26.18%)
      		1.53M
      ONMDOneMedNet Corporation
      $ 0.731999
      (115.29%)
      		461.26M
      HCTIHealthcare Triangle Inc
      $ 0.03225
      (4.03%)
      		304.86M
      TSLLDirexion Daily TSLA Bull 2X Trust ETF
      $ 13.815
      (-4.00%)
      		191.56M
      GNLNGreenlane Holdings Inc
      $ 0.00855
      (-3.93%)
      		126.21M
      NVDANVIDIA Corporation
      $ 147.335
      (2.20%)
      		124.6M

      MOLN Discussion

      View Posts
      Monksdream Monksdream 6 months ago
      MOLN, under $6


      👍️0
      OncoJock OncoJock 8 months ago
      Spoke with a research scientist today at the Memorial Sloan-Kettering Cancer Center who told me about MPO712, a radioDARPin targeted against DLL3-, which is a promising therapeutic target in a wide variety of aggressive tumors, including small cell lung cancer and the neuroendocrine form of prostate cancer. This scientist told me that there are now at least 20 drugs in development targeting DLL3, including bispecific antibodies, tri specific antibodies, radioligands, and antibody-drug conjugates. Apparently DARPins are an entirely new class of drugs, being pioneered by Molecular Partners. These drugs are characterized by structural simplicity and low molecular weight, in contrast to antibody-based drugs which are large, heavy macromolecules.

      A little research on the Molecular Partners website confirmed what the scientist told me, including that MPO712 is being prepared for entry into clinical trials in 2025. MOLN will also present posters about 2 other drugs next month at the annual meeting of the American Society of Hematology (ASH), one about MPO533 in acute myeloid leukemia, the other MPO621 an anti-CD47 agent designed as a conditioning agent for patients undergoing stem cell transplant.

      -- OJ
      👍️0
      Monksdream Monksdream 8 months ago
      MOLN under $6
      👍️0
      Awl416 Awl416 11 months ago
      Don’t blink
      👍️0
      Monksdream Monksdream 12 months ago
      MOLN
      👍️0
      Awl416 Awl416 1 year ago
      Whoops
      👍️0
      TimeFades TimeFades 1 year ago
      Short
      👍️0
      Man6677 Man6677 3 years ago
      MOLN $$$$

      https://stockcharts.com/h-sc/ui?s=MOLN


      https://finance.yahoo.com/news/molecular-partners-finalizes-license-agreement-060000110.html

      GLTA !
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Molecular Partners shares are trading higher after the company, and Novartis, reported topline data from the Phase 2 study for ensovibep, a DARPin antiviral therapeutic for COVID-19.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
      👍️0

      Your Recent History

      NASDAQ
      MOLN
      Molecular Partners
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads